Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor Reports Third Quarter 2023 Financial Results
04:01pm, Tuesday, 07'th Nov 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
04:01pm, Tuesday, 07'th Nov 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
12:01pm, Friday, 03'rd Nov 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis
Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?
01:31pm, Tuesday, 31'st Oct 2023
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xencor: Data In Early 2024 Could Bring Shareholder Value
11:56am, Friday, 27'th Oct 2023
Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-
Xencor: A Mid-Stage Clinical Company With Falling Losses
11:02pm, Friday, 20'th Oct 2023
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hemat
Xencor to Present Multiple Posters at the SITC Annual Meeting
09:01am, Wednesday, 27'th Sep 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise
Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript
03:20am, Sunday, 06'th Aug 2023
Xencor, Inc. (NASDAQ:XNCR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Na
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 per share a year ago.
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
08:01am, Thursday, 27'th Jul 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis
7 Battered Stocks That Could TRIPLE by 2024
08:38pm, Monday, 03'rd Jul 2023
Battered stocks to buy usually represent the exclusive avenue of the extreme speculator. As many beginner investors often find out, you don't want to take the buy low, sell high adage blindly without
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
07:03pm, Monday, 08'th May 2023
Xencor (XNCR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to earnings of $0.39 per share a year ago.
7 Biotech Stocks to Buy for 100% Returns
01:19pm, Sunday, 09'th Apr 2023
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
04:35am, Tuesday, 14'th Mar 2023
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
